GlassScriptPhysician profile
Kelsey Johnson
NPI 1790249951
$1,840.53
in general payments reported to CMS, 2019-2025
35 companies · $670 in 2025
The $670 reported for 2025 was more than what 76% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $375 · 2022: $215 · 2023: $95.98 · 2024: $484 · 2025: $670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,170 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,170.11 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $478.04 | 2022-2025 | |
| Leo Pharma INC. | $179.40 | 2024-2025 | Adbry |
| Janssen Biotech, INC. | $137.24 | 2024-2025 | Tremfya |
| Abbvie INC. | $111.09 | 2022-2025 | |
| Galderma Laboratories, L.P. | $82.83 | 2024-2025 | Aklief, Nemluvio |
| Amarin Pharma, INC. | $77.53 | 2021 | |
| Vyne Pharmaceuticals INC. | $52.02 | 2021 | |
| Corium, LLC | $51.98 | 2022 | |
| Janssen Pharmaceuticals, INC | $50.44 | 2021-2023 | Xarelto |
| Biofrontera INC. | $50.42 | 2021-2024 | Rhodoled Xl, Xepi, Bf-Rhodoled |
| Abbott Laboratories | $46.01 | 2023-2025 | Id Now Instrument, Freestyle Libre 2 |
| Ucb, INC. | $45.33 | 2022-2025 | Bimzelx |
| Pfizer INC. | $41.13 | 2024-2025 | |
| Xeris Pharmaceuticals, INC. | $37.76 | 2021 | |
| Merck Sharp & Dohme LLC | $34.72 | 2021-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.97 | 2021 | |
| Boston Scientific Corporation | $32.37 | 2023 | Wavewriter Alpha Prime 16 |
| Takeda Pharmaceuticals U.S.A., INC. | $29.10 | 2021 | |
| Sun Pharmaceutical Industries INC. | $22.82 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.45 | 2022 | |
| Botanix Sb INC | $18.52 | 2025 | Sofdra |
| Amgen INC. | $18.19 | 2024 | Otezla |
| Corcept Therapeutics | $17.77 | 2024 | Korlym |
| Almatica Pharma LLC | $17.41 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $16.92 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $15.97 | 2024 | Dupixent |
| Genentech USA, INC. | $14.83 | 2021 | |
| Treace Medical Concepts, INC. | $14.54 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.93 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.79 | 2024 | Zoryve |
| Dermavant Sciences, INC. | $13.62 | 2024 | Vtama |
| Bausch Health US, LLC | $13.53 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $12.43 | 2022 | |
| Organon LLC | $12.18 | 2022-2025 | Vtama |
| Medtronic, INC. | $11.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelsey Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.